Lilly’s Selpercatinib, Rinvoq’s Eczema Use Up for PAFSC Review on July 30

Eli Lilly Japan’s RET kinase inhibitor selpercatinib, known as Retevmo overseas, will come up for review by a key health ministry committee on July 30, with the panel’s nod, if given, putting it in line for approval as early as...read more